Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 73

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 73
---
095          -      1,095      100  
  Total revenue                                                                      9,587      7,143      2,444       34  
  Cost of sales                                                                                                            
  Active ingredients                                                                 4,706      4,205        501       12  
  Pharmaceutical                                                                       152          -        152      100  
  Total cost of sales                                                                4,858      4,205        653       16  
  Gross Margin                                                                       4,729      2,938      1,791       61  
  Gross Margin %                                                                        49         41                      

Our
total revenue for the twelve-month period ended December 31, 2024, was $9.6 million as compared to $7.1 million for the same period in
2023, an increase of $2.4 million. This increase was primarily due to a $1.3 million increase in sales of Avenanthramides, Beta Glucan
and Oat Oil from the prior period as well as a $1.1 million in Macrilen revenue due to the acquisition of Aeterna as described in the
plan of arrangement section above. Cost of sales for the twelve-month period ended December 31, 2024, increased by $0.7 million, primarily
due to the higher sales volumes during the period. The gross margin for the twelve-month period ended December 31, 2024, was $4.7 million
as compared to $2.9 million for the same period in 2023, an increase of $1.8 million. This increase is in line with the movements in
revenue and cost of sales and is primarily due to the high gross margin on pharmaceutical sales.

  52  

  (in thousands of US dollars, except percentages)      Year ended December 31,                                              
                                                        2023                                                                 
                                                        $                                                                    
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Revenue                                                                                                                    
  Active ingredients                                                                 7,143      14,572      (7,429      (51  
  Pharmaceutical                                                                         -           -           -        0  
  Total revenue                                                                      7,143      14,572      (7,429      (51  
  Cost of sales                                                                                                              
  Active ingredients                                                                 4,205       6,016      (1,811      (30  
  Pharmaceutical                                                                         -